Synovia is a nasty beast [Dissolution / BCS / IVIVC]

posted by dshah  – India/United Kingdom, 2022-01-10 16:31 (386 d 14:52 ago) – Posting: # 22728
Views: 1,296

Dear all!
The applicant wanted a wavier from Clinical end point study and so they have used a PBPK approach to prove that the levels of free drug in fluid are similar to reference product. As per the article- "The applicant conducted the PSG- recommended in vivo BE study with PK end points but did not perform the PSG- recommended comparative clinical end point study. Instead, the applicant developed a dermal PBPK model for a VBE assessment based on drug exposure at the presumed site of action between the reference and the test products."
The applicant choose- “the most accurate, sensitive, and reproducible approach available among those set forth" which is PK endpoint compared to clinical endpoint.
To further support- Q1, Q2 and Q3 (IVRT and IVPT) were compared against RLD.
Based on all the data- it is acceptable to presume that there is no significant difference between reference drug and applicant formulation. On the same basis- FDA has accepted the application.
Regards,
Dshah

Complete thread:

UA Flag
Activity
 Admin contact
22,477 posts in 4,708 threads, 1,603 registered users;
27 visitors (0 registered, 27 guests [including 11 identified bots]).
Forum time: 07:24 CET (Europe/Vienna)

I think it is much more interesting to live with uncertainty
than to live with answers that might be wrong.    Richard Feynman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5